Sir: We appreciate the thoughtful observations of Dr. Baker. It seems clear, as we concluded in our paper, that there is a need for further controlled research to confirm the positive findings so far achieved in open trials of risperidone augmentation of serotonin reuptake inhibitors (SRIs) in obsessive-compulsive disorder (OCD) and to obtain information about optimal dosage and duration of risperidone.